Legal and Policy Issues Currently Facing the Industry
Take a seat at the table as experts explore the current legal and policy issues impacting the generic drug and biosimilar supply chains–including drug shortages, efforts to onshore production of critical drugs in the U.S., and inefficient practices and loopholes employed to delay market entry.
Legal and Policy
Topics:
-
-
- Biosimilars at a Crossroads: Utilization Management and the Path to Sustainable Access
- FDA Legislative Developments: What to Expect in Potential Year-End Packages
- Patents in the 119th Congress: The Latest on Patent Settlements, Skinny Labeling, and Patent Thickets
- Tariffs, Trade & Onshoring in the Trump Administration
- Unintended Consequences: Biosimilar Reimbursement Policies and Their Impact on Sustainability
-
*Topics are subject to change
Who should attend:
Possible job titles include:
Regulatory Affairs, Medical Affairs, Business Development, Program Management, Policy, Commercial Development, Scientific Affairs, Research Analyst
About GRx+Biosims 2025
GRx+Biosims™ is the leading regulatory science and policy event for the U.S. generics and biosimilars industry. Get the latest information directly from Food and Drug Administration experts, understand the latest policy that impacts the industry and gain valuable insights to advance your professional development.
